Delta-Fly Pharma,Inc. [4598.T]
TOKYO, Jun 04 (Pulse News Wire) – Delta-fly Pharma,inc. (4598.T) reported today that the first patient enrollment has commenced for its physician-led clinical trial of DFP11,207 (an oral agent) for cholangiocarcinoma, conducted by the Japan Liver-Bile-Duct Oncology Network (JON-HBP).
The trial began in January 2026 under a contract between Delta-Fly Pharma and JON-HBP. It is being carried out across three facilities: Kanagawa Prefectural Cancer Center, Osaka International Cancer Center, and Saitama Prefectural Cancer Center.
Cholangiocarcinoma affects approximately 20,926 individuals annually, with around 17,232 deaths per year, making it one of the most challenging cancers in Japan, ranking sixth among cancer-related fatalities. The trial, which falls under the Clinical Research and Trials Submission/Publication System (JRCT), aims to advance treatment options for this difficult-to-treat condition.
Delta-Fly Pharma stated that it will continue to work closely with JON-HBP to ensure smooth collaboration throughout the duration of the study.
🟢 Confidence: High AI-translated content.